Revolutionary Hope: Indian Immunologicals Ltd and Australian University Unveil Cutting-Edge Needle-Free Intranasal COVID-19 Booster
Indian Immunologicals Ltd (IIL), a Hyderabad-based vaccine manufacturer, in collaboration with Griffith University, Australia, has developed a needle-free intra-nasal booster vaccine against SARS-CoV-2, as per a company press release. The innovative booster, using live-attenuated strains, employs ‘codon de-optimisation’ technology. This technique modifies the genetic code to reduce virus potency without altering the amino acid sequence, thus allowing controlled attenuation. Its efficacy and safety are underscored by its rapid development compared to conventional methods, which can span years. This breakthrough has been documented in the science journal, Nature Communications.
“This accomplishment signifies a major step forward in our battle against COVID-19. We are enthusiastic about the codon de-optimisation technology, and its use in targeted attenuation of microorganisms to be used as vaccine candidates,” stated K. Anand Kumar, managing director of IIL.
In a related development, Union Health Minister J.P. Nadda recently informed the Lok Sabha about the emergence of two highly transmissible COVID-19 strains, KP.1 and KP.2, derived from the JN1 Omicron variant. Although these strains have not led to a spike in hospitalizations or severe cases, they are under close surveillance.
As of December 2023, India has administered a total of 220.67 crore COVID-19 vaccine doses, with only 22.88 crore being booster doses among the eligible adult population, indicating a significant gap in precautionary vaccinations. This new intra-nasal booster could potentially address this gap by providing an easier, more accessible option for ongoing immunization efforts.
Original Story https://www.thehindu.com/sci-tech/health/indian-immunologicals-ltd-develops-needle-free-covid-19-intranasal-booster-vaccine-in-collaboration-with-australian-university/article68572222.ece
Category :
Tags:
